NYXH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nyxoah SA (NYXH) is not a strong buy for a beginner, long-term investor at this time. The stock shows bearish technical indicators, lacks positive trading signals, and has no recent news or catalysts to drive significant growth. Analysts have lowered price targets, and the company's financial data is unavailable for evaluation. While there is potential for long-term growth, the current market conditions and sentiment do not support an immediate buy decision.
The technical indicators for NYXH are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 36.803, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support levels are at 1.307 and 1.196, while resistance levels are at 1.666 and 1.777. The stock is trading below its pivot point of 1.486, indicating a weak price trend.
The Genio launch is progressing well, with U.S. net revenue up 25% quarter-over-quarter, as noted by Piper Sandler. Analysts believe Nyxoah has the potential to become a high-growth asset in the long term.
Analysts have consistently lowered price targets due to challenges in reimbursement for hypoglossal nerve stimulation (HGNS) and a challenging market environment. There is no recent news or significant trading activity from insiders, hedge funds, or Congress to support a bullish sentiment.
No financial data available for the latest quarter. The company's financial performance cannot be assessed due to missing data.
Analysts have a mixed to cautious outlook on NYXH. Stifel downgraded the stock to Hold from Buy and lowered the price target multiple times, citing reimbursement challenges and a preference for competitors like Inspire Medical. Piper Sandler maintains an Overweight rating but also lowered the price target, acknowledging the need for balance sheet improvements.
